+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Elevation of Serum Levels of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-1 and Type IV Collagen, and Plasma Levels of Metalloproteinase-9 in Polycystic Kidney Disease

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Several studies on polycystic kidney disease (PKD) have revealed a number of extracellular matrix (ECM) abnormalities, suggesting that an abnormal ECM plays a role in the development of tubular cysts. Cystic kidney tubules synthesize and secrete high levels of metalloproteinases (MMP), which may participate in the restructuring of the tubular basement membrane. The aim of the present study was to determine whether serum MMP-1, tissue inhibitor of metalloproteinase (TIMP)-1, and type IV collagen levels, and plasma MMP-9 levels were altered in patients with PKD. Sixteen patients with autosomal dominant polycystic kidney disease, and 20 healthy controls were included in this study. Specific enzyme immunoassays were used to measure MMP-1, MMP-9, TIMP-1, and type IV collagen levels. Serum MMP-1 (14.8 ± 3.6 ng/ml), TIMP-1 (288.6 ± 48.6 ng/ml), and type IV collagen (192.6 ± 38.8 ng/ml) concentrations, and plasma MMP-9 (90.2 ± 26.8 ng/ml) concentrations in patients with PKD were significantly higher than those in healthy controls (MMP-1; 6.6 ± 0.9 ng/ml, p < 0.01, MMP-9; 36.4 ± 12.2 ng/ml, p < 0.01, TIMP-1; 164.6 ± 22.8 ng/ml, p < 0.01, and type IV collagen; 86.6 ± 14.2 ng/ml, p < 0.001). The present results suggest that ECM abnormalities associated with cystic kidney may result from aberrant degradation as well as from abnormal synthesis of ECM components.

          Related collections

          Most cited references 4

          • Record: found
          • Abstract: found
          • Article: not found

          Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma.

          A 1 h, one-step sandwich enzyme immunoassay was set up with a pair of monoclonal antibodies prepared against bovine tissue inhibitor of metalloproteinases (TIMP). TIMP in samples was allowed to react simultaneously with both solid-phase antibody and peroxidase-labeled Fab' of another antibody. Minimum sensitivity was 1 pg/well for bovine TIMP and 1.5 pg/well for human TIMP. The TIMP level in the sera of 38 rheumatoid arthritis (RA) patients (241 +/- 53 ng/ml, mean +/- SD) was significantly higher (P less than 0.001) than the level in the sera of 81 healthy subjects (175 +/- 39). A similar significant difference (P less than 0.001) was observed between the TIMP level in platelet-poor plasma of normal subjects (64 +/- 10) and that of RA patients (84 +/- 23), suggesting that the increase in TIMP seen in RA sera can not be ascribed merely to an increase in platelet-derived TIMP.
            • Record: found
            • Abstract: not found
            • Article: not found

            A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies

              • Record: found
              • Abstract: not found
              • Article: not found

              A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies


                Author and article information

                Am J Nephrol
                American Journal of Nephrology
                S. Karger AG
                February 2000
                13 January 2000
                : 20
                : 1
                : 32-36
                aNephrology Unit, Misato Junshin Hospital, Saitama, and bDepartment of Medicine, Koto Hospital, Tokyo, Japan
                13552 Am J Nephrol 2000;20:32–36
                © 2000 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Tables: 3, References: 30, Pages: 5
                Self URI (application/pdf):
                Clinical Study


                Comment on this article